Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
2019 · British Journal of Cancer · 159 citations
https://doi.org/10.1038/s41416-019-0389-6
D
Derrick L. Tao
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
75
Papers
886
Citations
14
h-index
16
i10-index
Derrick L. Tao is an academic researcher from The University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Sarcoma Diagnosis and Treatment & Cancer Genomics and Diagnostics & CAR-T cell therapy research. The author has an h-index of 14, co-authored 64 publications.
ORCID: 0000-0001-5306-0259Papers by this author
worksCancer-induced nerve injury promotes resistance to anti-PD-1 therapy
2025 · Nature · 28 citations
https://doi.org/10.1038/s41586-025-09370-8
A Systematic Review and Meta-Analysis of Randomized Trials Examining Extended Thromboprophylaxis with Direct Oral Anticoagulants in Hospitalized Medical Patients
2016 · Blood · 1 citations
https://doi.org/10.1182/blood.v128.22.1436.1436
The responses of HNSCC patients to immunotherapy are shown by two novel co-expression patterns
2025 · npj Precision Oncology · 1 citations
https://doi.org/10.1038/s41698-025-00983-w
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat